Mohajerani E, Gümüs M, Dinger T F, Rieß C, Rauschenbach L, Rodemerk J, Ziegenfuß C D, Darkwah Oppong M, Ahmadipour Y, Li Y, Dammann P, Sure U, Jabbarli R
Department of Neurosurgery and Spine Surgery, University Hospital Essen, 45147, Essen, Germany.
Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, 45147, Essen, Germany.
Acta Neurochir (Wien). 2025 May 29;167(1):157. doi: 10.1007/s00701-025-06562-z.
Sarcopenia has already been investigated as a prognostic marker for many different cancerous and non-cancerous diseases to prognosticate the clinical course. While being a sarcopenia marker, temporal muscle thickness (TMT) has gained increasing interest in recent years as a potential outcome predictor. The aim of this retrospective study was to investigate the association between TMT and the neurological outcome of patients with aneurysmal subarachnoid hemorrhage (aSAH).
A retrospective database consisting of consecutive aSAH cases treated from 01/2003 to 06/2016 was used. The initial computed tomography examinations were used to calculate the mean TMT values. Our primary endpoint was unfavorable outcome at 6 months defined as modified Rankin Scale > 3. Secondary endpoints included the occurrence of angiographic vasospasm and intracranial hypertension (> 20mmHg) during aSAH, in-hospital mortality and development of cerebral infarcts. Univariable analyses were conducted and multivariable analyses were performed on significant findings.
The mean TMT value of the final cohort (n = 945) was 7.49mm ± 1.68mm. Of the baseline characteristics, a significant relationship with TMT mean value was found for age (p < 0.0001), sex (p < 0.0001), obesity (p = 0.001), hypothyroidism (p = 0.001), and hyperuricemia (p = 0.026). In the final multivariable analysis, the following study endpoints were independently associated with mTMT: in-hospital mortality (p = 0.035, adjusted odds ratio [aOR] 0.86 per-mm-increase, 95% confidence interval [CI] 0.75-0.99), unfavorable outcome at 6 months (p = 0.018, aOR 0.86, 95% CI 0.76-0.98), intracranial hypertension (p = 0.002, aOR 1.17, 95% CI 1.06-1.29) and the occurrence of angiographic vasospasm (p = 0.011, aOR 0.87, 95% CI 0.78-0.97).
In this study, we found significant correlations between mTMT and the clinical course and outcome of patients with aSAH. Further studies in different patient populations are needed to validate the clinical relevance and prognostic value of TMT for aSAH patients.
肌肉减少症已被作为许多不同癌症和非癌症疾病的预后标志物进行研究，以预测临床病程。作为一种肌肉减少症标志物，颞肌厚度（TMT）近年来作为一种潜在的预后预测指标越来越受到关注。这项回顾性研究的目的是探讨TMT与动脉瘤性蛛网膜下腔出血（aSAH）患者神经功能预后之间的关系。
使用一个回顾性数据库，该数据库由2003年1月至2016年6月连续治疗的aSAH病例组成。利用最初的计算机断层扫描检查来计算平均TMT值。我们的主要终点是6个月时不良预后，定义为改良Rankin量表评分>3。次要终点包括aSAH期间血管造影性血管痉挛和颅内高压（>20mmHg）的发生、住院死亡率和脑梗死的发生。进行单变量分析，并对显著结果进行多变量分析。
最终队列（n = 945）的平均TMT值为7.49mm±1.68mm。在基线特征中，发现年龄（p < 0.0001）、性别（p < 0.0001）、肥胖（p = 0.001）、甲状腺功能减退（p = 0.001）和高尿酸血症（p = 0.026）与TMT平均值有显著关系。在最终的多变量分析中，以下研究终点与mTMT独立相关：住院死亡率（p = 0.035，调整优势比[aOR]每增加1mm为0.86，95%置信区间[CI]0.75 - 0.99）、6个月时不良预后（p = 0.018，aOR 0.86，95%CI 0.76 - 0.98）、颅内高压（p = 0.002，aOR 1.17，95%CI 1.06 - 1.29）和血管造影性血管痉挛（血管造影性血管痉挛）的发生（p = 0.011，aOR 0.87，95%CI 查看全部翻译内容 0.78 - 0.97）。
在本研究中，我们发现mTMT与aSAH患者的临床病程和预后之间存在显著相关性。需要在不同患者群体中进行进一步研究，以验证TMT对aSAH患者的临床相关性和预后价值。
